171
Views
39
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia

, , , , , , , , , , , , , , , , & , MD show all
Pages 1104-1107 | Received 05 Feb 2008, Accepted 21 Mar 2008, Published online: 01 Jul 2009

References

  • Treon S P, Gertz M A, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan A R, et al. Update on treatment recommendations from the third international workshop on Waldenstrom's macroglobulinemia. Blood 2006; 107: 3442–3446
  • Morel P, Duhamel A, Gobbi P, Dimopoulos M, Dhodapkar M, McCoy J, et al. International Prognostic Scoring System (IPSS) for Waldenström's Macroglobulinemia (WM). Blood 2006; 108: 42a
  • Dhodapkar M V, Jacobson J L, Gertz M A, Rivkin S E, Roodman G D, Tuscano J M, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001; 98: 41–48
  • Mead G P, Carr-Smith H D, Drayson M T, Morgan G J, Child J A, Bradwell A R. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 348–354
  • Mayo M M, Johns G S. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias. Contrib Nephrol 2007; 153: 44–65
  • Durie B G, Harousseau J L, Miguel J S, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 2220
  • Rajkumar S V, Kyle R A, Therneau T M, Clark R J, Bradwell A R, Melton L J, III, et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol 2004; 127: 308–310
  • Gertz M A, Lacy M Q, Dispenzieri A, Hayman S R. Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma 2005; 6: 208–219
  • Owen R G, Treon S P, Al-Katib A, Fonseca R, Greipp P R, McMaster M L, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 110–115
  • Katzmann J A, Abraham R S, Dispenzieri A, Lust J A, Kyle R A. Diagnostic performance of quantitative κ and λ free light chain assays in clinical practice. Clin Chem 2005; 51: 878–881
  • Dispenzieri A, Lacy M Q, Katzmann J A, Rajkumar S V, Abraham R S, Hayman S R, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107: 3378–3383
  • Drayson M, Tang L X, Drew R, Mead G P, Carr-Smith H, Bradwell A R. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900–2902
  • Nowrousian M R, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11: 8706–8714
  • Dimopoulos M A, Kyle R A, Anagnostopoulos A, Treon S P. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23: 1564–1577
  • Ghobrial I M, Fonseca R, Gertz M A, Plevak M F, Larson D R, Therneau T M, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133: 158–164

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.